All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Join our
Treating classical Hodgkin lymphoma: Spotlight on targeted therapies
with Gilles Salles, Paul Bröckelmann, and Ann S. LaCasce
Saturday, November 2, 2024
8:50-9:50 CET
This independent educational activity is sponsored by Takeda. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.
The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. Digital educational resources delivered on the Multiple Myeloma Hub are supported by an educational grant from Janssen Biotech, Inc. View funders.
Primary objective met in the DREAMM-2 trial of belantamab mafodotin in relapsed/refractory multiple myeloma
By Alia Mohamed
On 23rd August 2019, headline results from the pivotal DREAMM-2 open-label, two-arm, randomized, phase II study of belantamab mafodotin (NCT03525678) were released.1 Belantamab mafodotin is an investigational anti-B-cell maturation antigen (BCMA) antibody-drug conjugate and the DREAMM-2 trial investigated the safety and efficacy at two doses in 196 patients with relapsed or refractory (R/R) multiple myeloma (MM) who had received more than three prior treatments, failed an anti-CD38 antibody and were refractory to a proteasome inhibitor and an immunomodulatory drug.
DREAMM-2 met its primary endpoint demonstrating a clinically meaningful overall response rate (ORR) and the safety profile was consistent with that observed in the preceding phase I trial - DREAMM-1.1
The results from DREAMM-2 will form the basis of regulatory submission for belantamab mafodotin, which is expected by the end of 2019.
Currently there are ongoing studies which are investigating belantamab mafodotin as third-line monotherapy in R/R MM and as a combination therapy in first- and second-line treatment.
- GlaxoSmithKline. GSK announces positive headline results from the pivotal DREAMM-2 study for multiple myeloma. https://www.gsk.com/en-gb/media/press-releases/gsk-announces-positive-headline-results-from-the-pivotal-dreamm-2-study-for-multiple-myeloma/ [Accessed August 27 2019]
Your opinion matters
47 votes - 9 days left ...
Newsletter
Subscribe to get the best content related to multiple myeloma delivered to your inbox